Last updated: September 7, 2026
Bezlotoxumab, marketed by Merck as Zinplava, is a monoclonal antibody approved to reduce recurrence of Clostridioides difficile infection in adults and pediatric patients aged at least 1 year who receive antibacterial treatment for C. difficile infection. Its commercial trajectory peaked shortly after launch and then declined as hospitals faced administration barriers, reimbursement pressure, a narrow treatment window, competing microbiota-based products, and evolving guideline preferences.
Merck reported Zinplava sales of approximately $31 million in 2022, down from about $44 million in 2021, $75 million in 2020, and $91 million in 2019. The product represented roughly 0.05% of Merck's 2022 revenue. The principal remaining commercial questions are the duration of Merck's biologic exclusivity, the likelihood of a biosimilar, and whether bezlotoxumab remains commercially viable against Rebyota and Vowst.
What is bezlotoxumab and how does it work?
Bezlotoxumab is a fully human monoclonal antibody that binds toxin B produced by C. difficile. It is administered as a single intravenous infusion alongside antibacterial therapy. It does not treat the active bacterial infection directly and is not a substitute for vancomycin, fidaxomicin, or other antibacterial treatment.
| Attribute |
Details |
| Brand |
Zinplava |
| Active ingredient |
Bezlotoxumab |
| Sponsor |
Merck & Co., Inc. |
| Product type |
Human monoclonal antibody |
| Target |
C. difficile toxin B |
| Route |
Intravenous infusion |
| Dosing |
One 10 mg/kg infusion |
| FDA approval |
October 21, 2016 |
| Primary indication |
Reduction of recurrence of C. difficile infection |
| Key risk |
Heart-failure warning in patients with a history of congestive heart failure |
| Commercial category |
Hospital-administered specialty biologic |
The pivotal MODIFY I and MODIFY II trials showed lower recurrence rates with bezlotoxumab than with placebo when administered with standard-of-care antibacterial therapy. The treatment effect was most commercially relevant in patients with prior C. difficile infection or other recurrence risk factors, including advanced age, severe disease, immunocompromise, and infection with a high-risk strain (Wilcox et al., 2017).
How has the financial trajectory of Zinplava changed?
Zinplava sales declined sharply after the initial launch period. Merck's reported figures show a fall of approximately 66% from 2019 to 2022.
| Year |
Merck-reported Zinplava sales |
Year-over-year change |
| 2017 |
Approximately $84 million |
Not comparable |
| 2018 |
Approximately $125 million |
Increase |
| 2019 |
Approximately $91 million |
Decrease |
| 2020 |
Approximately $75 million |
Decrease |
| 2021 |
Approximately $44 million |
Decrease |
| 2022 |
Approximately $31 million |
Decrease |
Sources: Merck annual reports and Form 10-K filings for the relevant years.
The 2018 result appears to have been the product's high-water mark. Sales then weakened despite the underlying recurrence burden of C. difficile infection remaining substantial. The decline reflects product-specific adoption problems rather than the disappearance of the clinical need.
What drove the decline in bezlotoxumab revenue?
Several factors limited uptake.
First, bezlotoxumab is an adjunctive treatment. A patient must already be receiving antibacterial therapy and must be identified as having sufficiently high recurrence risk to justify an additional hospital-administered biologic.
Second, the product requires intravenous administration, infusion capacity, drug acquisition, and coordination between inpatient and outpatient care. These requirements are less convenient than oral fidaxomicin and newer oral microbiota products.
Third, reimbursement has been a constraint. Hospitals and physicians may bear acquisition and administration costs while the financial benefit of preventing a recurrence occurs later and may accrue to another payer or care setting.
Fourth, the label's heart-failure warning reduced use in an important high-risk population. In the MODIFY trials, heart-failure adverse events and deaths were more frequent among patients with a history of congestive heart failure who received bezlotoxumab than among comparable placebo-treated patients (FDA, 2022).
Fifth, guideline positioning has been selective. The 2021 IDSA/SHEA focused update suggested bezlotoxumab for patients with a recurrent episode within the prior six months and identified it as a possible option for selected high-risk primary episodes. The recommendation was conditional and based on low certainty of evidence, which limited broad adoption (Johnson et al., 2021).
What is the FDA regulatory status of Zinplava?
The FDA approved Zinplava on October 21, 2016, under a biologics license application. The approved use is prevention of recurrence, not treatment of the active infection.
The FDA label contains several commercially relevant restrictions:
- Bezlotoxumab must be used with antibacterial treatment for C. difficile infection.
- It is administered as a single 10 mg/kg intravenous dose.
- The product is not indicated for treatment of active C. difficile infection.
- Use in patients with a history of congestive heart failure should be reserved for cases in which the benefit outweighs the risk.
- Pediatric labeling was later expanded to patients aged at least 1 year.
The FDA-approved patient population is narrower than the total C. difficile market. The commercial opportunity depends on identifying patients at high risk of recurrence before discharge or during treatment, then arranging infusion within the appropriate treatment window.
What patents and exclusivity protect bezlotoxumab?
Bezlotoxumab is protected primarily by biologic regulatory exclusivity, manufacturing know-how, clinical data, and antibody-related patent rights rather than by a conventional small-molecule Orange Book patent estate.
Does Zinplava have an Orange Book listing?
No conventional Orange Book strategy should be assumed for Zinplava. The Orange Book is designed primarily for approved drug products and associated patents submitted under the Hatch-Waxman framework. Therapeutic monoclonal antibodies approved under a biologics license application are generally evaluated through the Purple Book and the Biologics Price Competition and Innovation Act pathway.
The relevant regulatory protection is therefore:
| Protection category |
Relevance to bezlotoxumab |
| FDA biologic approval |
Granted October 21, 2016 |
| Reference-product exclusivity |
Generally 12 years from first licensure under the BPCIA |
| Estimated end of reference-product exclusivity |
October 21, 2028, absent an applicable extension |
| Orange Book patent certification |
Generally not the primary pathway |
| Biosimilar pathway |
BPCIA, including patent-information exchange and possible patent litigation |
| Pediatric extension |
No widely reported extension should be assumed without a current FDA exclusivity record |
Under the BPCIA, a biosimilar referencing a licensed biologic generally cannot be approved for marketing until 12 years after the reference product was first licensed. On that basis, bezlotoxumab's reference-product exclusivity would run to approximately October 2028, subject to FDA determinations and any applicable exclusivity adjustment (Biologics Price Competition and Innovation Act, 2010; FDA, 2024).
How strong is the patent estate for bezlotoxumab?
The commercial patent estate is difficult to assess through a simple Orange Book expiration-date search. Potential protection may include:
- Antibodies binding C. difficile toxin B.
- Specific antibody sequences and variants.
- Antibody production and purification methods.
- Cell lines and expression systems.
- Formulation and stability claims.
- Combination use with antibacterial therapy.
- Methods for reducing recurrence in defined patient populations.
The practical strength of the estate depends on claim scope, written-description support, prosecution history, terminal disclaimers, patent-term adjustment, and whether later patents cover the commercial antibody sequence or only broader antibody classes.
The most important near-term barrier to a competitor is likely the combination of biologic exclusivity, manufacturing complexity, clinical comparability requirements, and patent litigation risk. The commercial value of additional patent protection is limited by the product's declining revenue and the availability of competing recurrence-prevention products.
When does bezlotoxumab lose exclusivity?
The key date is October 21, 2028, when the standard 12-year BPCIA reference-product exclusivity period would expire based on the FDA approval date. A biosimilar could not receive final approval before that date solely by relying on the reference product's biologic data.
This date does not guarantee immediate biosimilar entry. A competitor would still need to complete a biosimilar development program, file a BLA, address manufacturing comparability, resolve patent disputes, and secure FDA approval. The first practical market entry could occur after 2028, depending on the development and litigation timetable.
Because Zinplava sales had already fallen to approximately $31 million by 2022, the commercial incentive for a standalone biosimilar program is limited. A biosimilar developer may require a broader anti-infective portfolio, hospital contracting platform, or manufacturing infrastructure to justify the investment.
Are there Paragraph IV challenges to Zinplava?
Paragraph IV certification is generally associated with the Hatch-Waxman pathway for small-molecule drugs and Orange Book-listed patents. It is not the standard mechanism for challenging a monoclonal antibody approved under a biologics license application.
For bezlotoxumab, the relevant competitive challenge would be a biosimilar application under the BPCIA, not a conventional Abbreviated New Drug Application with a Paragraph IV certification.
No major public biosimilar litigation against Zinplava had materially altered the product's market position through the publicly reported 2022-2024 period. The absence of a public biosimilar challenge is consistent with the product's modest revenue base and complex clinical positioning.
Which products compete with bezlotoxumab?
Bezlotoxumab competes with both direct recurrence-prevention products and treatment strategies that reduce the need for recurrence prevention.
| Product or strategy |
Sponsor |
Delivery |
Competitive effect |
| Bezlotoxumab |
Merck |
One-time IV infusion |
Established antibody option for high-risk patients |
| Rebyota |
Ferring |
Rectal microbiota-based product |
Direct recurrence-prevention competitor |
| Vowst |
Seres Therapeutics, later acquired by Nestlé Health Science |
Oral microbiota spores |
Oral alternative after antibacterial treatment |
| Fidaxomicin |
Merck and generic manufacturers |
Oral antibacterial |
Reduces recurrence relative to vancomycin in some settings |
| Vancomycin |
Multiple manufacturers |
Oral antibacterial |
Low-cost standard therapy |
| Fecal microbiota transplantation |
Multiple providers |
Procedural or microbiota-based |
Alternative for recurrent disease |
The approval of Rebyota in November 2022 and Vowst in April 2023 changed the recurrence-prevention market. These products gave clinicians options that avoid the infusion-center logistics associated with bezlotoxumab, although each has its own eligibility, handling, reimbursement, and evidence requirements (FDA, 2022; FDA, 2023).
How does bezlotoxumab compare with Rebyota and Vowst?
Bezlotoxumab has the advantage of a defined mechanism, a single infusion, and a longer commercial history. It also has the disadvantage of requiring intravenous administration and carrying a heart-failure warning.
Rebyota and Vowst are microbiota-based products intended to restore or supplement the intestinal microbiome after antibacterial treatment. Their oral or rectal delivery may fit recurrence-prevention workflows more naturally than an intravenous antibody, although payer coverage and provider familiarity remain important constraints.
Vowst is particularly relevant because oral administration can eliminate the need for infusion capacity. That competitive advantage may be strongest in outpatient and post-discharge settings, where Zinplava has historically faced operational friction.
What is the biosimilar risk for bezlotoxumab?
The near-term biosimilar risk is low because reference-product exclusivity extends to approximately 2028 and the product's revenue base is small. The longer-term risk is moderate in principle but uncertain in commercial execution.
A biosimilar developer would face:
- Complex cell-based manufacturing.
- Analytical similarity requirements for a monoclonal antibody.
- Clinical pharmacology and immunogenicity studies.
- Limited addressable revenue.
- Competition from microbiota-based products.
- Potential patent litigation under the BPCIA.
- Hospital contracting pressure that could reduce the value of a premium-priced entrant.
A biosimilar could still enter if priced substantially below Zinplava or bundled with a broader infectious-disease portfolio. The most likely entry strategy would target hospitals and integrated delivery networks seeking lower acquisition costs rather than attempt to expand the overall market.
What patent litigation and settlement agreements affect Zinplava?
No major publicly reported settlement agreement or litigation outcome had become a central commercial determinant for Zinplava through the publicly available 2022-2024 information period.
The absence of visible litigation does not mean the product lacks patent protection. It indicates that no public BPCIA challenge had yet created a defined launch date or settlement-based entry schedule. Any future dispute would likely involve patent information exchanged during the biosimilar process, followed by litigation over antibody composition, sequence, formulation, manufacturing, or method-of-use claims.
What licensing deals support bezlotoxumab?
No material external licensing transaction has been publicly identified as a principal driver of Zinplava's commercial economics. Merck has controlled the product's development and commercialization. The product is therefore more directly exposed to Merck's internal portfolio decisions, hospital sales infrastructure, and infectious-disease strategy than to royalty obligations arising from a major third-party license.
That structure reduces royalty leakage but does not solve the product's market-access problems. Declining demand, administration costs, and competition have been more important than licensing expense.
What is the geographic coverage of bezlotoxumab?
Zinplava received regulatory approval in the United States and was marketed in other jurisdictions, including Europe, under Merck's global commercial infrastructure. The market opportunity is concentrated in developed healthcare systems with:
- High documented recurrence rates.
- Hospital reimbursement for biologic infusion.
- Specialist infectious-disease involvement.
- Access to C. difficile diagnostic testing.
- Payer willingness to cover recurrence-prevention therapy.
Emerging-market penetration is constrained by biologic cost, infusion infrastructure, and competing low-cost antibacterial therapies. Geographic patent and regulatory coverage must be assessed jurisdiction by jurisdiction because biologic exclusivity periods, patent terms, and biosimilar approval standards differ.
What generic launch scenarios exist for bezlotoxumab?
A conventional generic launch is unlikely because bezlotoxumab is a biologic. The relevant scenarios are:
- A biosimilar launches after the estimated October 2028 exclusivity date.
- A biosimilar launches later after patent litigation or settlement.
- No biosimilar launches because the market is too small and competing products have taken share.
- Merck maintains limited availability for high-risk patients while the product becomes a niche hospital therapy.
- Merck withdraws or materially reduces commercial support if net revenue no longer covers manufacturing and distribution costs.
The fourth and fifth scenarios are more commercially plausible than a large post-exclusivity erosion event. A biosimilar could reduce price but may not materially expand use because the central barriers are clinical selection, reimbursement, and administration logistics.
What is the investment and commercial outlook for bezlotoxumab?
Bezlotoxumab is no longer a meaningful revenue driver for Merck. At approximately $31 million in 2022 sales, it contributed less than one-tenth of one percent of Merck's total revenue. Its financial importance is therefore limited, but its patent and regulatory position remains relevant to:
- Specialty anti-infective portfolio strategy.
- Hospital contracting.
- Biosimilar development decisions.
- C. difficile recurrence-prevention guidelines.
- Valuation of any assets or rights transferred outside Merck.
- Manufacturing capacity allocation for monoclonal antibodies.
The product's strongest remaining commercial position is in patients with a high recurrence risk for whom clinicians prefer an established antibody and can secure infusion reimbursement. Its weakest position is in outpatient settings where oral Vowst or microbiota-based alternatives reduce operational complexity.
Key Takeaways
- Zinplava sales declined from approximately $91 million in 2019 to $31 million in 2022.
- Merck's product revenue peaked around 2018 and has since contracted.
- The product is a single-dose IV antibody used with antibacterial therapy, not a treatment for active C. difficile infection.
- The estimated BPCIA reference-product exclusivity date is October 21, 2028.
- Paragraph IV litigation is not the relevant challenge mechanism; biosimilar competition would proceed under the BPCIA.
- No major public biosimilar litigation or settlement had established an entry date through the publicly reported 2022-2024 period.
- Rebyota and Vowst have increased competitive pressure, particularly because they provide microbiota-based recurrence-prevention options.
- A conventional generic launch is not expected.
- A biosimilar launch after 2028 is possible but may be unattractive because of low revenue and competing products.
- Zinplava is financially immaterial to Merck but remains relevant in infectious-disease portfolio and biologic-exclusivity analysis.
FAQs About Bezlotoxumab Market and Patent Risk
Is bezlotoxumab still commercially available?
The product's commercial availability has varied by market and over time. Merck's declining reported sales indicate a substantially reduced commercial footprint compared with the launch period.
What is the price of a dose of Zinplava?
The historical U.S. wholesale acquisition cost was commonly reported at roughly $4,500 for a 70 kg adult dose, before administration, rebates, discounts, and payer adjustments. Actual net pricing varies by site of care and contract.
Can a generic company make bezlotoxumab?
A conventional generic company cannot use the standard small-molecule ANDA pathway. A competitor would generally need to develop and file a biosimilar under the BPCIA.
Is bezlotoxumab more effective than fidaxomicin?
The products operate differently. Bezlotoxumab is given with antibacterial therapy to reduce recurrence, while fidaxomicin treats the active infection and may itself reduce recurrence compared with vancomycin. They are not direct substitutes in every patient.
Does bezlotoxumab have orphan-drug exclusivity?
The principal regulatory protection is biologic reference-product exclusivity, not a broadly relied-upon orphan-drug exclusivity period. The relevant exclusivity analysis should focus on the BPCIA 12-year period and any identified patent-term extensions.
References
-
Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7002, 124 Stat. 119 (2010).
-
Food and Drug Administration. (2022). Zinplava (bezlotoxumab) prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov
-
Food and Drug Administration. (2022). FDA approves first fecal microbiota product. U.S. Department of Health and Human Services. https://www.fda.gov
-
Food and Drug Administration. (2023). FDA approves first orally administered fecal microbiota product for preventing recurrence of Clostridioides difficile infection. U.S. Department of Health and Human Services. https://www.fda.gov
-
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services. https://purplebooksearch.fda.gov
-
Johnson, S., Lavergne, V., Skinner, A.-M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H. (2021). Clinical practice guideline by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America: 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases, 73(5), e1029-e1044. https://doi.org/10.1093/cid/ciab549
-
Merck & Co., Inc. (2018-2023). Annual reports and Form 10-K filings. https://www.merck.com
-
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Lee, C., Jenkin, G. A., et al. (2017). Bezlotoxumab for prevention of recurrent Clostridium difficile infection. New England Journal of Medicine, 376(4), 305-317. https://doi.org/10.1056/NEJMoa1602615
